Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.
作者信息
Tran Agnès, Bournerias François, Le Beller Christine, Mir Olivier, Rey Elisabeth, Pons Gérard, Delahousse Michel, Tréluyer Jean-Marc
出版信息
Br J Clin Pharmacol. 2008 Feb;65(2):279-80. doi: 10.1111/j.1365-2125.2007.03020.x. Epub 2007 Sep 13.
Abstract
摘要
相似文献
1
Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms.环磷酰胺与CYP2B6、GSTA1和GSTP1基因多态性相关的严重血液学毒性。
Br J Clin Pharmacol. 2008 Feb;65(2):279-80. doi: 10.1111/j.1365-2125.2007.03020.x. Epub 2007 Sep 13.
2
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.药物代谢酶（CYP2B6、CYP2C9、CYP2C19、CYP3A4、CYP3A5、GSTA1、GSTP1、ALDH1A1和ALDH3A1）多态性对环磷酰胺和4-羟基环磷酰胺药代动力学的影响。
Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766.
3
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.药物代谢酶（谷胱甘肽S-转移酶、细胞色素P450 2B6和细胞色素P450 3A）的多态性会影响噻替派和替派的药代动力学。
Br J Clin Pharmacol. 2009 Jan;67(1):50-60. doi: 10.1111/j.1365-2125.2008.03321.x. Epub 2008 Nov 17.
4
Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.环磷酰胺代谢途径中的基因多态性、治疗相关毒性与 SWOG8897 乳腺癌临床试验中的无病生存
Clin Cancer Res. 2010 Dec 15;16(24):6169-76. doi: 10.1158/1078-0432.CCR-10-0281.
5
[Association between CYP2B6, CYP2D6, GSTP1 genetic polymorphisms and urinary styrene metabolites in professional workers].
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2009 Oct;27(10):589-92.
6
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.环磷酰胺药物代谢酶多态性与乳腺癌幸存者化疗相关卵巢衰竭的关联。
Fertil Steril. 2010 Jul;94(2):645-54. doi: 10.1016/j.fertnstert.2009.03.034. Epub 2009 Apr 18.
7
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.CYP2B6的基因多态性影响日本癌症患者中环磷酰胺的药代动力学/药效学。
Pharmacogenet Genomics. 2007 Jun;17(6):431-45. doi: 10.1097/FPC.0b013e328045c4fb.
8
Influence of genetic polymorphisms of styrene-metabolizing enzymes and smoking habits on levels of urinary metabolites after occupational exposure to styrene.苯乙烯代谢酶基因多态性及吸烟习惯对职业性接触苯乙烯后尿代谢产物水平的影响。
Toxicol Lett. 2005 Dec 30;160(1):84-91. doi: 10.1016/j.toxlet.2005.06.011. Epub 2005 Aug 25.
9
The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status.关于环磷酰胺代谢状态正确确定CYP2B6基因变异的重要性。
Am J Hematol. 2011 Apr;86(4):383-4; author reply 384. doi: 10.1002/ajh.21987.
10
Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.依非韦伦与细胞色素P450 2B6基因多态性：对药物毒性和耐药性的影响
Clin Infect Dis. 2006 Feb 1;42(3):408-10. doi: 10.1086/499369. Epub 2005 Dec 27.
引用本文的文献
1
Influence of Genetic Variation of GST, CYP, and ABC on the Safety and Efficacy of Cyclophosphamide-Based Therapy.谷胱甘肽S-转移酶、细胞色素P450和ATP结合盒转运蛋白的基因变异对环磷酰胺治疗安全性和有效性的影响
Clin Transl Sci. 2025 Jul;18(7):e70301. doi: 10.1111/cts.70301.
2
Gene polymorphisms associated with immunosuppressant adverse effects in systemic lupus erythematosus: a narrative review.系统性红斑狼疮中与免疫抑制剂不良反应相关的基因多态性：一项叙述性综述
Front Genet. 2025 Jun 24;16:1594648. doi: 10.3389/fgene.2025.1594648. eCollection 2025.
3
gene polymorphisms are associated with cyclophosphamide effectiveness in lupus nephritis patients: A case-control study in Indonesia.基因多态性与狼疮性肾炎患者环磷酰胺疗效相关：印度尼西亚的一项病例对照研究。
Narra J. 2024 Dec;4(3):e1144. doi: 10.52225/narra.v4i3.1144. Epub 2024 Nov 15.
4
Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety.系统性红斑狼疮的合成药物治疗：作用机制、疗效和安全性的潜在机制。
Medicina (Kaunas). 2022 Dec 27;59(1):56. doi: 10.3390/medicina59010056.
5
Possible Susceptibility Genes for Intervention against Chemotherapy-Induced Cardiotoxicity.干预化疗引起的心脏毒性的可能易感性基因。
Oxid Med Cell Longev. 2020 Oct 13;2020:4894625. doi: 10.1155/2020/4894625. eCollection 2020.
6
High-resolution melt analysis to detect sequence variations in highly homologous gene regions: application to CYP2B6.高分辨率熔解分析检测高度同源基因区域的序列变异：在 CYP2B6 中的应用。
Pharmacogenomics. 2013 Jun;14(8):913-22. doi: 10.2217/pgs.13.66.
7
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.药物代谢酶基因型与乳腺癌患者环磷酰胺血药浓度及骨髓毒性的关系。
Eur J Clin Pharmacol. 2012 Apr;68(4):389-95. doi: 10.1007/s00228-011-1134-0. Epub 2011 Oct 20.
本文引用的文献
1
Clinical pharmacokinetics of cyclophosphamide.环磷酰胺的临床药代动力学
Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003.
2
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.血液系统恶性肿瘤患者中环磷酰胺的药物遗传学
Eur J Pharm Sci. 2006 Jan;27(1):54-61. doi: 10.1016/j.ejps.2005.08.008. Epub 2005 Sep 23.
3
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19.环磷酰胺药代动力学与细胞色素P450 2C19基因多态性的关联
Pharmacogenomics J. 2005;5(6):365-73. doi: 10.1038/sj.tpj.6500330.
4
Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.谷胱甘肽S-转移酶π特异性抑制剂O1-十六烷基-γ-谷氨酰-S-苄基半胱氨酰-D-苯甘氨酸乙酯逆转胆管癌中的多药耐药性
J Pharmacol Exp Ther. 2003 Sep;306(3):861-9. doi: 10.1124/jpet.103.052696. Epub 2003 Jun 12.
5
Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.谷胱甘肽S-转移酶A1启动子多态性与乳腺癌治疗后生存率之间的关联。
Int J Cancer. 2003 Mar 1;103(6):810-4. doi: 10.1002/ijc.10896.
6
Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli.人类谷胱甘肽S-转移酶P1基因的等位基因变体对大肠杆菌中的抗癌药物具有不同的细胞保护作用。
Pharmacogenetics. 2002 Oct;12(7):543-53. doi: 10.1097/00008571-200210000-00006.
Zotero 插件